US 12350241 B1Patent grantUnited States

Aromatic Compound for Cancer Cell Screening

Official patent title

Method for inhibiting proliferation of cancer cells

Arabic title: طريقة لتثبيط تكاثر الخلايا السرطانية

Invention

Problem

Cancer therapies may have limited effectiveness, high cost, and toxicity to healthy tissue. Additional small-molecule leads are needed for laboratory evaluation across different tumor-cell models and in combination with existing agents.

Why it matters

A reproducibly synthesized compound that shows broad cell-growth inhibition can provide a starting point for studying structure, potency, selectivity, apoptotic response, and combination effects in preclinical oncology research.

Approach

The method contacts cancer-cell models with a Formula (II) compound identified as 4-(4-butoxyphenoxy)benzaldehyde, alone or with doxorubicin. The compound is made by reacting a phenol and benzaldehyde under basic conditions and heat.

Who may benefit

Potential beneficiaries include medicinal-chemistry teams, oncology laboratories, pharmaceutical lead-discovery groups, combination-therapy researchers, and organizations developing cell-based treatment-selection assays.

Potential value

The disclosure links a defined, readily synthesized aromatic aldehyde to approximately 90% growth inhibition across several listed cancer-cell models at specified in-vitro concentrations and reports improved inhibition with doxorubicin at a reduced compound amount.

Background

Cancer-cell proliferation and resistance involve altered growth, death, and inflammatory signaling. Apoptosis-related pathways therefore remain important targets for small-molecule discovery. Existing treatments can be costly and can damage healthy cells, so new compounds are screened across cell lines before animal or clinical development. The disclosed aromatic aldehyde is evaluated in several listed cancer-cell models and in combination with doxorubicin. These cell-culture results are preliminary: potency at high test concentrations does not establish selectivity, systemic safety, achievable exposure, or therapeutic benefit.

Technology overview

Formula (II), described as 4-(4-butoxyphenoxy)benzaldehyde, is synthesized by mixing a phenol compound and benzaldehyde compound with potassium or sodium carbonate and heating at 120–160 °C. In-vitro contact tests cover HEP2, A549, HCT116, PC3, FaDu, MDA-MB-468, and HeLa models. Claims report about 90% growth inhibition at 6,000–10,000 μg/mL, with model-specific ranges, and state that adding doxorubicin improves inhibition at a reduced amount compared with the compound alone.

Potential applications

In-vitro anticancer lead screening across multiple cell models.
Combination-effect studies with doxorubicin.
Medicinal-chemistry optimization of aromatic aldehyde analogues.
Cell-based response and biomarker assay development.

Evidence-supported advantages

Uses a defined two-reactant, base-assisted synthesis route.
Reports growth-inhibition measurements across several cancer-cell models.
Includes a combination experiment with doxorubicin.
Provides model-specific in-vitro concentration ranges.
Offers a compact aromatic scaffold for analogue research.

Development stage

Compound synthesis and in-vitro growth-inhibition testing across several cancer-cell models are described; normal-cell selectivity, animal efficacy, pharmacology, toxicology, and clinical performance were not established. The development stage was not independently verified.

Commercial opportunity

The compound may support early oncology lead licensing or sponsored validation. Advancement requires confirmation at lower and pharmacologically relevant exposures, normal-cell selectivity, mechanism and apoptosis assays, combination-index analysis, formulation, pharmacokinetics, animal efficacy and toxicology, scalable synthesis, regulatory review, and clinical trials.

Patent classifications

WIPO IPC

A61K31/09Preparations for medical, dental or toiletry purposes
A61P35/00Specific therapeutic activity of chemical compounds or medicinal preparations

CPC

A61K31/09Preparations for medical, dental or toiletry purposes
A61P35/00Specific therapeutic activity of chemical compounds or medicinal preparations
G01N33/5758Investigating or analysing materials by determining their chemical or physical properties
G01N2800/52Investigating or analysing materials by determining their chemical or physical properties

Inventors

First inventorTarek Ahmed Yousef
InventorSaad Shaaban
InventorHussein Ba-Ghazal
InventorAyman Abo Elmaaty
InventorAhmed A. Al-Karmalawy

Keywords

cancer cell proliferation
4-(4-butoxyphenoxy)benzaldehyde
Formula II
doxorubicin
in-vitro assay
growth inhibition
medicinal chemistry
oncology lead

Patent document and drawings

The patent publication is mapped to this record. Patent drawings remain within that publication; no separately cleared public media package has been supplied.